Drug developer Impax Laboratories, Inc. (IPXL) announced Wednesday that the U.S. Food and Drug Administration or FDA has given final approval of Impax's Abbreviated New Drug Application or ANDA for generic version of the anticonvulsant drug Depakote 500mg Extended-release Tablets.
The company received approval on the 250 mg tablets in May this year. Abbott Laboratories markets the divalproex-containing drug for the treatment of epilepsy and bipolar disorders. Impax revealed that it is looking forward to launching both versions of the tablets immediately, through its generic division, Global Pharmaceuticals.
According to the medical publisher Wolters Kluwer Health, U.S. sales of Depakote ER 250 mg for the year ended June 30, 2009 were $93 million and sales of 500mg tablets were around $633 million.
IPXL is currently trading at $7.43, down $0.05 or 0.67%, on the NASDAQ.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.